[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Myriad Genetics Inc (MYGN)

Myriad Genetics Inc (MYGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Myriad Genetics Names Raj Jampa as New Chief Technology Officer

SALT LAKE CITY, June 02, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announces today the appointment of Raj Jampa...

MYGN : 4.22 (-1.40%)
Myriad Genetics Highlights Data Showing Broad Clinical Utility of Precise MRD Assay at 2026 ASCO Annual Meeting

SALT LAKE CITY, May 27, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announces it will share data demonstrating the...

MYGN : 4.22 (-1.40%)
Myriad Genetics Launches Prolaris® + AI, the First Prostate Cancer Test to Combine Genomics and Digital Pathology Artificial Intelligence (AI)

SALT LAKE CITY, May 26, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announces the launch of the Prolaris + AI Test...

MYGN : 4.22 (-1.40%)
1 Unprofitable Stock to Consider Right Now and 2 We Turn Down

1 Unprofitable Stock to Consider Right Now and 2 We Turn Down

GEVO : 1.8300 (-0.54%)
MYGN : 4.22 (-1.40%)
PI : 145.99 (+2.33%)
Actress Jackie Tohn Got Results Nobody Wants But They May Have Saved Her Life

SALT LAKE CITY, May 15, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, joins forces with Nobody Wants This actress...

MYGN : 4.22 (-1.40%)
Myriad Genetics’s Q1 Earnings Call: Our Top 5 Analyst Questions

Myriad Genetics’s Q1 Earnings Call: Our Top 5 Analyst Questions

MYGN : 4.22 (-1.40%)
3 of Wall Street’s Favorite Stocks with Open Questions

3 of Wall Street’s Favorite Stocks with Open Questions

AR : 36.16 (-1.63%)
DLTR : 111.52 (+0.15%)
MYGN : 4.22 (-1.40%)
Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences

SALT LAKE CITY, May 07, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc . (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced Myriad management will participate...

MYGN : 4.22 (-1.40%)
MYGN Q1 Deep Dive: Hereditary Cancer Strength, Launch Investments Pressure Margins

MYGN Q1 Deep Dive: Hereditary Cancer Strength, Launch Investments Pressure Margins

MYGN : 4.22 (-1.40%)
Myriad: Q1 Earnings Snapshot

Myriad: Q1 Earnings Snapshot

MYGN : 4.22 (-1.40%)

Barchart Exclusives

Why Okta Is One of the Hottest AI-Driven Stocks to Buy Now
Okta's AI-driven turnaround is gaining momentum as strong earnings and higher guidance fuel a sharp stock rally. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.